Previous 10 | Next 10 |
MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten public offering of 4,860,000 shares of its common stock at a price to the public of $35.00 p...
December 10, 2019 Palm Beach, FL –December 10, 2019 – There are so many paths that R&D is taking in the ongoing fight against cancer. New drugs, new therapies and new techniques are developed to help researchers and practitioners across all cancer sub-markets. One su...
Technical Communications (NASDAQ: TCCO ) +260% after Q4 results . More news on: Technical Communications Corporation, Equillium, Inc., CounterPath Corporation, Stocks on the move, Read more ...
Shares of Forty Seven (NASDAQ: FTSV) rose as much as 95.6% today after the company provided an encouraging update for its lead drug candidate at the Annual Meeting of the American Society of Hematology. The oddly named company is developing the monoclonal antibody magrolimab as a treatment f...
Gainers: Synthorx (NASDAQ: THOR ) +170% . More news on: Synthorx, Inc., ArQule, Inc., Forty Seven, Inc., Stocks on the move, Read more ...
Thinly traded Forty-Seven ( FTSV +83.7% ) is up on a healthy 28x surge in volume in response to updated data from an ongoing Phase 1b clinical trial evaluating lead candidate magrolimab (5F9), combined with chemo agent azacitidine (Celgene's Vidaza), in treatment-naïve patien...
-- Expect to Initiate Phase 1 Clinical Trial in Healthy Volunteers in First Quarter of 2020 -- -- Forty Seven to Host Investor Event and Webcast at 8:00 p.m. ET -- MENLO PARK, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology ...
-- CR Rate of 50% and ORR of 92% Observed in Untreated Patients with Higher-Risk MDS -- -- CR/CRi Rate of 55% and ORR of 64% Observed in Patients with Untreated AML Who are Ineligible for Induction Chemotherapy -- -- Median Duration of Response Not Yet Reached, with Patients on Tr...
Image source: The Motley Fool. Forty Seven Inc (NASDAQ: FTSV) Q3 2019 Earnings Call Nov 12, 2019 , 5:00 p.m. ET Operator Continue reading
Forty Seven, Inc. (FTSV) Q3 2019 Earnings Conference Call November 12, 2019 8:00 AM ET Company Participants Michael Horowicz – Stern Investor Relations Mark McCamish – Chief Executive Officer Ann Rhoads – Chief Financial Officer Mark Chao – Founder a...
News, Short Squeeze, Breakout and More Instantly...
The ongoing COVID-19 pandemic has caused significant disruptions to the global economy, as well as grievances for families witnessing their loved ones die from the virus. Fortunately, there's finally a light at the end of the tunnel as one investigative treatment has revealed potential efficacy ...
For years, Gilead Sciences ' (NASDAQ: GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over ...
Shares of Forty Seven (NASDAQ: FTSV) climbed 64.5% in March, according to data from S&P Global Market Intelligence . The immuno-oncology specialist's stock skyrocketed early in the month after it was announced that the company was on track to be purchased by Gilead Sciences...